There's a morose metaphor that seasoned drug developers often use to sum up decades of failed efforts to find treatments for Alzheimer's disease: They call the mind-robbing condition "the graveyard of drug development." But lately, sentiments have started to shift, with the arrival of Leqembi, a new drug approved by federal regulators in January.
